Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK)

HKD 1.3

(-2.99%)

Market Cap (In HKD)

1.02 Billion

Revenue (In HKD)

63.52 Million

Net Income (In HKD)

-359.11 Million

Avg. Volume

596.54 Thousand

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.25-3.71
PE
-
EPS
-
Beta Value
0.542
ISIN
KYG4987A1094
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Yinxiang Wang
Employee Count
-
Website
https://www.jacobiopharma.com
Ipo Date
2020-12-21
Details
Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It is also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-1 resistant cancer; JAB-6343, an inhibitor that targets fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma with FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. Jacobio Pharmaceuticals Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, China.